Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more
Oscotec Inc (039200) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.064x
Based on the latest financial reports, Oscotec Inc (039200) has a cash flow conversion efficiency ratio of -0.064x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-7.92 Billion) by net assets (₩122.94 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oscotec Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Oscotec Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oscotec Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oscotec Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coursera Inc
NYSE:COUR
|
0.009x |
|
Xiamen King Long Motor Group Co Ltd
SHG:600686
|
-0.128x |
|
Fortrea Holdings Inc.
NASDAQ:FTRE
|
0.149x |
|
Bank Handlowy w Warszawie SA
WAR:BHW
|
-0.153x |
|
CIE Automotive S.A
PINK:CUOTF
|
0.033x |
|
Mesnac Co Ltd
SHE:002073
|
0.028x |
|
Data Patterns (India) Limited
NSE:DATAPATTNS
|
-0.032x |
|
Tianjin Guangyu Development Co Ltd
SHE:000537
|
0.106x |
Annual Cash Flow Conversion Efficiency for Oscotec Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Oscotec Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩132.36 Billion | ₩-26.03 Billion | -0.197x | +15.50% |
| 2023-12-31 | ₩94.72 Billion | ₩-22.05 Billion | -0.233x | -7.93% |
| 2022-12-31 | ₩122.51 Billion | ₩-26.42 Billion | -0.216x | +29.04% |
| 2021-12-31 | ₩28.83 Billion | ₩-8.76 Billion | -0.304x | +9.83% |
| 2020-12-31 | ₩53.05 Billion | ₩-17.88 Billion | -0.337x | -63035.38% |
| 2019-12-31 | ₩51.29 Billion | ₩27.47 Million | 0.001x | +100.49% |
| 2018-12-31 | ₩46.29 Billion | ₩-5.08 Billion | -0.110x | +36.83% |
| 2017-12-31 | ₩21.24 Billion | ₩-3.69 Billion | -0.174x | +44.31% |
| 2016-12-31 | ₩26.33 Billion | ₩-8.21 Billion | -0.312x | -1397.65% |
| 2015-12-31 | ₩26.92 Billion | ₩646.84 Million | 0.024x | +126.68% |
| 2014-12-31 | ₩21.78 Billion | ₩-1.96 Billion | -0.090x | -166.09% |
| 2012-12-31 | ₩24.47 Billion | ₩3.34 Billion | 0.136x | +832.77% |
| 2011-12-31 | ₩25.73 Billion | ₩375.90 Million | 0.015x | -- |